

# **Canine Leishmaniasis Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023**

<https://marketpublishers.com/r/C699ED8E980EN.html>

Date: November 2017

Pages: 219

Price: US\$ 4,400.00 (Single User License)

ID: C699ED8E980EN

## **Abstracts**

### **Global Canine Leishmaniasis Management Market**

Canine leishmaniasis is a vector-borne disease caused by the *Leishmania infantum* and *Leishmania chagasi*. Canine leishmaniasis is transmitted through the infected Phlebotominae flies. The severity of the canine leishmaniasis leads to the death of animals and high risk of disease transmission in humans and other dogs. The primary symptoms associated with the canine leishmaniasis include asthenia, anaemia, cachexia, weight loss, skin lesions, and muscular atrophy. In the later stage the symptoms like abnormal growth of nails, conjunctivitis, and renal failure may occur in the canines. The canine leishmaniasis can be prevented by administering the vaccines initially 3 doses with 3-week interval between them and an annual dose which increase the immunity in the canines.

The canine leishmaniasis management market is growing at a significant CAGR due to increase in adoption of canines. A rise in the prevalence of canine *Leishmania*, increase in the research and development for new vaccines for canine leishmaniasis management, rise in the expenditure for animal welfare and wellness, and patent filings for the various canine leishmaniasis management formulations might fuel the canine leishmaniasis management market over the forecast years. However, stringent regulatory policies for the approval of new vaccines for the canine leishmaniasis management, storage of vaccines, lack of awareness regarding canine leishmaniasis management, increase in the canine culling process, and dearth of canine leishmaniasis management products in the market might hamper the canine leishmaniasis

management market growth in the forecast years.

Canine leishmaniasis management market is segmented on the basis of product type, disease type, route of administration, and end user

Based on the product type, canine leishmaniasis management market is segmented into the following:

- Canine leishmaniasis prevention

  - Vaccines

- Canine leishmaniasis treatment

  - Antibiotics

    - Polyene antibiotics (Amphotericin B)

    - Marbofloxacin

    - Others

    - Miltefosine

    - Meglumine antimoniate

    - Pentavalent antimonials

    - Allopurinol combinations

    - Paromomycin

    - Others

Based on the disease type, canine leishmaniasis management market is segmented into the following:

- Visceral leishmaniasis

Cutaneous leishmaniasis

Mucocutaneous leishmaniasis

Based on the route of administration, canine leishmaniasis management market is segmented into the following:

Oral

Parenteral

Topical

Based on the distribution channel, canine leishmaniasis management market is segmented into the following:

Veterinary clinics

Veterinary pharmacies

Online pharmacies

NGO's

Others

Global canine leishmaniasis management market is in the developing stage with several international players are actively involved in the development of formulations for the treatment and prevention of canine leishmaniasis. Increase in the research and development for canine leishmaniasis vaccines, product approval from various regulatory bodies such as EMEA and FDA, and launching of new products into the market might fuel the canine leishmaniasis management market over the forecast period. For instance, in March 2011, EMEA approved the marketing authorization in the Europe region for CaniLeish vaccine manufactured by Virbac S.A. Similarly, US Food and Drug Administration scientists are working with India and Brazil scientists for the

development of a non-virulent vaccine to treat visceral leishmaniasis in canines.

Geographically, canine leishmaniasis management market is segmented into the following regions Viz. Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. Europe holds significant share in the global canine leishmaniasis management market owing to the presence of tropical and subtropical areas which are favourable for the growth of sand flies. Spain, France, Greece, Italy and some other European countries have the highest prevalence of canine leishmaniasis. Increase in the research and development for Leishmania vaccines, rise in the expenditure of animal welfare and growing awareness about the canine leishmaniasis treatment might bolster the market. Asia Pacific canine leishmania management market growth over the forecast years attributed to poor hygienic conditions in the rural area, increase in the canine adoption rate, and the environmental conditions that favour the growth of sand flies. Increase in the canine leishmaniasis prevalence rate majorly in India, China, Bangladesh, Saudi Arabia, and UAE might fuel the canine leishmaniasis management market. North America holds a reasonable share due to increase in the adoption rate of canines (according to American Pet Products Association, approximately 78 Mn canines were owned in the U.S.).

Some of the players in canine leishmaniasis management market are Zoetis, Inc. (Pfizer) (U.S), Hertape Calier Saude Animal S.A. (Brazil), Virbac AH Inc. (France), Laboratories Leti (Spain), Bioiberica S.A. (Spain), and Sanofi S.A. (France) to name a few.

In September 2016, European commission authorized the marketing of Letifend vaccine manufactured by Laboratories Leti to treat canine leishmaniasis

#### Report Outline:

The report provides granular level information about the market size, regional market share, and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings, and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments, and startup's details

that are working in the industry

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET INTRODUCTION**

#### 2.1. Global Canine Leishmaniasis Management Market– Taxonomy

#### 2.2. Global Canine Leishmaniasis Management Market–Definitions

##### 2.2.1. Product Type

##### 2.2.2. Disease Type

### **3. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET DYNAMICS**

#### 3.1. Drivers

#### 3.2. Restraints

#### 3.3. Opportunities/Unmet Needs of the Market

#### 3.4. Trends

#### 3.5. Global Canine Leishmaniasis Management Market Dynamics – Factors Impact Analysis

#### 3.6. Global Canine Leishmaniasis Management Market– Recent Market Introductions

### **4. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023**

#### 4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 4.3. Market Opportunity Analysis

### **5. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023**

#### 5.1. Vaccines

##### 5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

##### 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

##### 5.1.3. Market Opportunity Analysis

#### 5.2. Antibiotics

##### 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

##### 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

##### 5.2.3. Market Opportunity Analysis

### 5.3. Miltefosine

- 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.3.3. Market Opportunity Analysis

### 5.4. Meglumine Antimoniate

- 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.4.3. Market Opportunity Analysis

### 5.5. Pentavalent Antimonials

- 5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.5.3. Market Opportunity Analysis

### 5.6. Allopurinol Combinations

- 5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.6.3. Market Opportunity Analysis

### 5.7. Paromomycin

- 5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.7.3. Market Opportunity Analysis

### 5.8. Others

- 5.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.8.3. Market Opportunity Analysis

## **6. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 6.1. Visceral Leishmaniasis

- 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.1.3. Market Opportunity Analysis

### 6.2. Cutaneous Leishmaniasis

- 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.2.3. Market Opportunity Analysis

### 6.3. Mucocutaneous Leishmaniasis

- 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

### 6.3.3. Market Opportunity Analysis

## **7. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 7.1. Oral

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

### 7.2. Parenteral

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

### 7.3. Topical

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

## **8. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 8.1. Veterinary clinics

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

### 8.2. Veterinary pharmacies

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

### 8.3. Online pharmacies

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

### 8.4. NGO's

8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

### 8.5. Others

8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)



8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

## **9. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

### **9.1. North America**

9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.1.3. Market Opportunity Analysis

### **9.2. Europe**

9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.2.3. Market Opportunity Analysis

### **9.3. Asia-Pacific**

9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.3.3. Market Opportunity Analysis

### **9.4. Latin America**

9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.4.3. Market Opportunity Analysis

### **9.5. Middle East and Africa**

9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.5.3. Market Opportunity Analysis

9.6. Global Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

## **10. NORTH AMERICA CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.1.1. Canine Leishmaniasis Prevention

10.1.1.1.1. Vaccines

10.1.1.2. Canine Leishmaniasis Treatment

10.1.1.3. Antibiotics

- 10.1.1.3.1. Polyene Antibiotics (Amphotericin B)
- 10.1.1.3.2. Marbofloxacin
- 10.1.1.3.3. Others
- 10.1.1.4. Miltefosine
- 10.1.1.5. Meglumine Antimoniate
- 10.1.1.6. Pentavalent Antimonials
- 10.1.1.7. Allopurinol Combinations
- 10.1.1.8. Paromomycin
- 10.1.1.9. Others
- 10.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 10.1.2.1. Visceral Leishmaniasis
  - 10.1.2.2. Cutaneous Leishmaniasis
  - 10.1.2.3. Mucocutaneous Leishmaniasis
- 10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 10.1.3.1. Oral
  - 10.1.3.2. Parenteral
  - 10.1.3.3. Topical
- 10.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 10.1.4.1. Veterinary Clinics
  - 10.1.4.2. Veterinary Pharmacies
  - 10.1.4.3. Online Pharmacies
  - 10.1.4.4. NGO's
  - 10.1.4.5. Others
- 10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  - 10.1.5.1. U.S.
  - 10.1.5.2. Canada
- 10.1.6. North America Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
- 10.1.7. North America Canine Leishmaniasis Management Market Dynamics – Trends

## **11. EUROPE CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 11.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue

(USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.1.1. Canine Leishmaniasis Prevention

11.1.1.1.1. Vaccines

11.1.1.2. Canine Leishmaniasis Treatment

11.1.1.3. Antibiotics

11.1.1.3.1. Polyene Antibiotics (Amphotericin B)

11.1.1.3.2. Marbofloxacin

11.1.1.3.3. Others

11.1.1.4. Miltefosine

11.1.1.5. Meglumine Antimoniate

11.1.1.6. Pentavalent Antimonials

11.1.1.7. Allopurinol Combinations

11.1.1.8. Paromomycin

11.1.1.9. Others

11.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Visceral Leishmaniasis

11.1.2.2. Cutaneous Leishmaniasis

11.1.2.3. Mucocutaneous Leishmaniasis

11.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Oral

11.1.3.2. Parenteral

11.1.3.3. Topical

11.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.4.1. Veterinary Clinics

11.1.4.2. Veterinary Pharmacies

11.1.4.3. Online Pharmacies

11.1.4.4. NGO's

11.1.4.5. Others

11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.5.1. Germany

11.1.5.2. UK

11.1.5.3. France

11.1.5.4. Spain

11.1.5.5. Italy

11.1.5.6. Russia

11.1.5.7. Poland

11.1.5.8. Rest of Europe

11.1.6. Europe Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023

11.1.7. Europe Canine Leishmaniasis Management Market Dynamics – Trends

## **12. ASIA-PACIFIC CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

12.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.1.1. Canine Leishmaniasis Prevention

12.1.1.1.1. Vaccines

12.1.1.2. Canine Leishmaniasis Treatment

12.1.1.3. Antibiotics

12.1.1.3.1. Polyene Antibiotics (Amphotericin B)

12.1.1.3.2. Marbofloxacin

12.1.1.3.3. Others

12.1.1.4. Miltefosine

12.1.1.5. Meglumine Antimoniate

12.1.1.6. Pentavalent Antimonials

12.1.1.7. Allopurinol Combinations

12.1.1.8. Paromomycin

12.1.1.9. Others

12.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Visceral Leishmaniasis

12.1.2.2. Cutaneous Leishmaniasis

12.1.2.3. Mucocutaneous Leishmaniasis

12.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Oral

12.1.3.2. Parenteral

12.1.3.3. Topical

12.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Veterinary Clinics

12.1.4.2. Veterinary Pharmacies

12.1.4.3. Online Pharmacies

12.1.4.4. NGO's

12.1.4.5. Others

12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

12.1.5.1. Japan

12.1.5.2. China

12.1.5.3. India

12.1.5.4. ASEAN

12.1.5.5. Australia & New Zealand

12.1.5.6. Rest of Asia-Pacific

12.1.6. Asia-Pacific Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023

12.1.7. Asia-Pacific Canine Leishmaniasis Management Market Dynamics – Trends

### **13. LATIN AMERICA CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

13.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.1.1. Canine Leishmaniasis Prevention

13.1.1.1.1. Vaccines

13.1.1.2. Canine Leishmaniasis Treatment

13.1.1.3. Antibiotics

13.1.1.3.1. Polyene Antibiotics (Amphotericin B)

13.1.1.3.2. Marbofloxacin

13.1.1.3.3. Others

13.1.1.4. Miltefosine

13.1.1.5. Meglumine Antimoniate

13.1.1.6. Pentavalent Antimonials

13.1.1.7. Allopurinol Combinations

13.1.1.8. Paromomycin

13.1.1.9. Others

13.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Visceral Leishmaniasis

13.1.2.2. Cutaneous Leishmaniasis

#### 13.1.2.3. Mucocutaneous Leishmaniasis

13.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

##### 13.1.3.1. Oral

##### 13.1.3.2. Parenteral

##### 13.1.3.3. Topical

13.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

##### 13.1.4.1. Veterinary Clinics

##### 13.1.4.2. Veterinary Pharmacies

##### 13.1.4.3. Online Pharmacies

##### 13.1.4.4. NGO's

##### 13.1.4.5. Others

13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

##### 13.1.5.1. Brazil

##### 13.1.5.2. Mexico

##### 13.1.5.3. Argentina

##### 13.1.5.4. Venezuela

##### 13.1.5.5. Rest of Latin America

13.1.6. Latin America Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023

13.1.7. Latin America Canine Leishmaniasis Management Market Dynamics – Trends

## **14. MIDDLE EAST & AFRICA CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

14.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

#### 14.1.1.1. Canine Leishmaniasis Prevention

##### 14.1.1.1.1. Vaccines

#### 14.1.1.2. Canine Leishmaniasis Treatment

#### 14.1.1.3. Antibiotics

##### 14.1.1.3.1. Polyene Antibiotics (Amphotericin B)

##### 14.1.1.3.2. Marbofloxacin

##### 14.1.1.3.3. Others

#### 14.1.1.4. Miltefosine

#### 14.1.1.5. Meglumine Antimoniate

- 14.1.1.6. Pentavalent Antimonials
- 14.1.1.7. Allopurinol Combinations
- 14.1.1.8. Paromomycin
- 14.1.1.9. Others
- 14.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 14.1.2.1. Visceral Leishmaniasis
  - 14.1.2.2. Cutaneous Leishmaniasis
  - 14.1.2.3. Mucocutaneous Leishmaniasis
- 14.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 14.1.3.1. Oral
  - 14.1.3.2. Parenteral
  - 14.1.3.3. Topical
- 14.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 14.1.4.1. Veterinary Clinics
  - 14.1.4.2. Veterinary Pharmacies
  - 14.1.4.3. Online Pharmacies
  - 14.1.4.4. NGO's
  - 14.1.4.5. Others
- 14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 14.1.5.1. Gulf Cooperation Council (GCC) Countries
  - 14.1.5.2. Israel
  - 14.1.5.3. South Africa
  - 14.1.5.4. Rest of MEA
- 14.1.6. MEA Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
- 14.1.7. MEA Canine Leishmaniasis Management Market Dynamics – Trends

## **15. COMPETITION LANDSCAPE**

- 15.1. Strategic Dashboard of Top Market Players
- 15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  - 15.2.1. Zoetis, Inc. (Pfizer) (U.S)
  - 15.2.2. Hertape Calier Saude Animal S.A. (Brazil)

15.2.3. Virbac AH Inc. (France)

15.2.4. Laboratories Leti (Spain)

15.2.5. Bioiberica S.A. (Spain)

## **16. RESEARCH METHODOLOGY**

## **17. KEY ASSUMPTIONS AND ACRONYMS**



## I would like to order

Product name: Canine Leishmaniasis Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Product link: <https://marketpublishers.com/r/C699ED8E980EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C699ED8E980EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

